Fundacao Pio XII

The trials here

What the 26 trials at this site are about, from their registry records.

Conditions

• Lung cancer7 trials
• Bladder cancer5 trials
• Multiple myeloma3 trials
• Prostate cancer3 trials
• Colorectal cancer2 trials
• Acute myeloid leukaemia1 trial
• Childhood cancers1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Head and neck cancer1 trial
• Melanoma1 trial
• Ovarian cancer1 trial

Phase

• Phase 321 trials
• Phase 23 trials
• Phase 1/22 trials

Status

• Active, not recruiting15 trials
• Recruiting7 trials
• Completed4 trials

Lead sponsor

• Janssen Research & Development, LLC20 trials
• Johnson & Johnson Enterprise Innovation Inc.2 trials
• Novo Nordisk A/S1 trial
• Nuvalent Inc.1 trial
• Pfizer1 trial
• and 1 more

Running trials

• Recruiting

  Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

  NCT06765109· Phase 3· Nuvalent Inc.· Source

  Contact: Josiane Mourao Dias, MD (principal investigator)

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

  NCT06750094· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

  NCT06667908· Phase 2· Johnson & Johnson Enterprise Innovation Inc.· Source

• Recruiting

  A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

  NCT06662786· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  NCT06319820· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

  NCT06211764· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

  NCT05884398· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer

  NCT05908734· Phase 1/2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

  NCT05714202· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

  NCT05498428· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

  NCT05455320· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

  NCT05388669· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

  NCT04892173· Phase 3· Johnson & Johnson Enterprise Innovation Inc.· Source

• Active, not recruiting

  Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

  NCT04906395· Phase 3· Tolmar Inc.· Source

• Active, not recruiting

  Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

  NCT04822181· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

  NCT04658862· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

  NCT04538664· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT04487080· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

  NCT04497844· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

  NCT03748641· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

  NCT03473743· Phase 1/2· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• Colorectal cancer2 recruiting
• Acute myeloid leukaemia1 recruiting
• Head and neck cancer1 recruiting

Closed trials

• Recruiting

  A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

  NCT05552222· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

  NCT04083976· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT03277105· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

  NCT01909453· Phase 3· Pfizer· Source